4 assets in Optic Neuritis

Therapeutic assets addressing Optic Neuritis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fampridine Optic Neuritis	Courtney Casserly	P2/3	BB (67)
Privosegtor Optic Neuritis	Oculis	P3	B (60)
Clemastin Optic Neuritis	University of California, San Francisco	P2	CCC (53)
Mutated Human Immunoglobulin G1 Fc Fragment Anti-(Homo Sapiens Igg Receptor Fcrn Large Subunit P51 (Neonatal Fc Receptorfcrn))(37-Tyr(M>Y(32),39-Thr(S>T(34),41-Glu(T>E(36),218-Lys(H>K(213)),219-Phe(N>F(214))(Fc Fragment Of Human Immunoglobulin Heavy Constant Gamma 1)-(6-232)-Peptide, Dimer (6-6':9-9')-Bisdisulfide, Produced In Cho Cells, Glycoform Alfa Optic Neuritis	Anastasia Vishnevetsky, MD, MPH	P2	CCC (53)